Fig. 4: MYC downregulation induced by S63845 treatment leads to STAT1 upregulation and activation of Type I IFN signaling pathways.
From: Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma
A Heatmap showing increasing expression of CXCL9, CXCL10 and CXCL11 in parental B-cell lymphoma cell lines (HBL-2, U2932 and REC-1) treated with the IC50 doses of S63845 at different time points as indicated. B Heatmap showing elevated levels of STAT1, CXCL10, CXCL11, and genes associated with IFN and inflammation in MYC knockdown DHL-16 and Z138 cells compared to parental cell lines. C Heatmap showing elevated levels of STAT1, CXCL9, CXCL10, CXCL11, and genes associated with IFN and inflammation in HBL-2 parental and STAT1 knockdown cells treated with the IC50 doses of S63845 for 7 days. D Heatmap showing elevated levels of STAT1, CXCL9, CXCL10, CXCL11, and genes associated with IFN and inflammation in STAT1 knockdown HBL-2 and DHL-16 S63845 resistance cells. E Correlation plots showing positive association between STAT1 mRNA levels and CXCL9, CXCL10, CXCL11 mRNA levels in aggressive B-cell lymphoma patient samples (DLBCL, orange; BL, purple). F ChIP using STAT1-specific antibody showing STAT1 enrichment at the promoters of genes involved in CXCL9, CXCL10, CXCL11 and genes associated with IFN and inflammation.
